Macrogenics Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | Macrogenics Inc.

Macrogenics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

260.80

38,313.00

20,140.00

58,528.00

19,626.00

171,453

Depreciation, Depletion & Amortization

1,193.30

1,822.00

2,863.00

7,608.00

7,228.00

8,279

Other Funds

1,113.50

3,244.00

7,847.00

12,165.00

14,744.00

16,520

Funds from Operations

2,046.00

33,247.00

9,430.00

38,755.00

2,346.00

146,654

Changes in Working Capital

16,218.10

383.00

4,231.00

4,924.00

12,059.00

6,580

Net Operating Cash Flow

14,172.10

32,864.00

13,661.00

43,679.00

14,405.00

153,234

Capital Expenditures

2,960.80

3,572.00

9,197.00

11,381.00

29,403.00

Purchase/Sale of Investments

142,910.00

58,868.00

107,279.00

Net Investing Cash Flow

2,960.80

3,572.00

152,107.00

70,249.00

77,876.00

Net Financing Cash Flow

85,871.20

77,441.00

204,349.00

1,854.00

35,348.00

Net Change in Cash

68,738.30

41,005.00

38,581.00

112,074.00

127,629.00

Free Cash Flow

17,132.90

36,436.00

22,858.00

55,060.00

14,998.00

Change in Capital Stock

85,871.20

77,441.00

204,349.00

1,854.00

35,348.00

About Macrogenics

View Profile

Address	9740 Medical Center Drive Rockville Maryland 20850 United States
Employees	-
Website	http://www.macrogenics.com
Updated	07/08/2019
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E.